The low engraftment rate of stem/progenitor cells infused via the intracoronary route to the ischemic myocardium is one of the most important factors limiting the efficacy of cell therapy. We investigated the concept of priming peripheral blood stem cells enriched by granulocyte colony-stimulating factor mobilization and apheresis ( mob PBSCs) with angiopoietin-1 (Ang1), to enhance the engraftment into the ischemic tissue and neovasculogenic potential. Methods and Results-The expression of Tie2, the Ang1 receptor, was significantly higher in mob PBSCs than naïve peripheral blood mononuclear cells (19.2Ϯ3.0% versus 1.2Ϯ0.8% versus 1.2Ϯ0.2%; PϽ0.001 for mob PBSCs from acute myocardial infarction (AMI) patients with granulocyte colony-stimulating factor treatment for 3 days versus peripheral blood mononuclear cells from AMI patients versus peripheral blood mononuclear cells from stable angina patients).
T he identification of various types of bone marrowderived stem/progenitor cells has raised the possibility that cell therapy can be a promising therapeutic modality to repair ischemic cardiovascular tissues. 1 Recent clinical trials demonstrated that intracoronary infusion of bone marrowderived cells may improve the outcome of acute myocardial infarction (AMI) patients. 2, 3 Among delivery strategies of cell therapy for patients with MI, the intracoronary delivery of the cells is the most convenient and commonly used. We have studied the characteristics of circulating peripheral blood stem/progenitor cells 4 and have demonstrated clinical application of the intracoronary infusion of peripheral blood stem cells enriched by granulocyte colony-stimulating factor (G-CSF) mobilization and apheresis ( mob PBSCs) in patients with MI. 5 However, the low efficiency of engraftment (ie, 1% to 3%) to the ischemic myocardium is one of the most important hurdles in improving the efficacy of cell therapy. 6, 7 Accordingly, we aimed to find a new method of augmenting neovascularization by overcoming the poor engraftment of mob PBSCs into ischemic tissue and enhancing its endothelial lineage commitment.
Clinical Perspective on p 2250
Experimental studies have reported that ex vivo genetic modification and pretreatment with small molecules enhanced cellular function. 8, 9 Relative to the safety concern of genetic manipulation and the clinical applicability of small molecules, it would be an attractive method to augment engraftment and induce lineage commitment of mob PBSCs by the short-term, protein-based, ex vivo stimulation of stem/ progenitor cells. This short-term stimulation for boosting the neovasculogenic potential of mob PBSC is called priming.
Angiopoietin-1 (Ang1) is a growth factor binding to the Tie2 receptor expressed on endothelial cells (ECs) and hematopoietic stem cells. Through Tie2 signaling, Ang1 plays an essential role in postnatal angiogenesis by mediating vessel maturation and maintaining vessel integrity. 10 However, little is known about its role in the engraftment and lineage commitment of stem cells and in the modulation of its downstream pathway.
In the present study, we found that mob PBSCs highly expressed Tie2 compared with naïve peripheral blood mononuclear cells (PBMCs) obtained from patients with AMI. Therefore, we investigated the effects of priming naïve PBMCs and mob PBSCs using Ang1 in vitro and in vivo. The short-term Ang1 stimulation of mob PBSCs, but not naïve PBMCs, augmented endothelial lineage commitment and engraftment through the Tie2/Ets-1 signaling pathway and eventually enhanced the neovasculogenic potential in the ischemic tissue.
Methods
All experiments dealing with humans or human products were conducted with informed consent and approved by the Institutional Review Board of Seoul National University Hospital. All animal experiments were performed after receiving approval from the Institutional Animal Care and Use Committee of the Clinical Research Institute of the Seoul National University Hospital and complied with the National Research Council Guidelines for the Care and Use of Laboratory Animals.
Statistical Analysis
One-way ANOVA with Tukey posthoc analysis was used to compare Ն3 groups with regard to continuous response variables, and the Pearson 2 test was used to analyze categorical data. In the Table, the differences between 3 groups were analyzed with the Welch test for one-way ANOVA with the Tamhane method because of unequal within-group variances. In the experiment for in vivo perfusion recovery, repeated-measures ANOVA with Scheffé contrasts was used to quantify the main effects of 4 groups and time and significant interactions. The calculation was performed with SAS version 9.1 (SAS Institute, Inc, Cary, NC). The other calculations were performed with SPSS version 13.0 (SPSS Inc, Chicago, Ill), and values of PϽ0.05 were considered statistically significant. Detailed experimental methods are described in the online-only Data Supplement.
Results mob PBSCs Highly Express Tie2 Compared With PBMCs
We obtained mob PBSCs that were PBMCs after 3 days of G-CSF subcutaneous injection from 33 AMI patients enrolled in the Myocardial Regeneration in Acute and Old MI With G-CSF Mobilization and Intra-Coronary Stem Cell Infusion (MAGIC-Cell) program. 5 We also selected PBMCs from 15 AMI patients without G-CSF treatment (PBMC_AMI) as a control for mobilized PBSCs from AMI patients. In addition, we selected PBMCs from 20 patients with stable angina (PBMC_SA) as another control for the disease of AMI. The characteristics of the patients are shown in Table I of the  online-only Data Supplement. We characterized mob PBSCs and PBMCs by flow cytometry analysis. We found that mob PBSCs contained more cells positive for KDR, CD34, and CD133, which are major surrogate markers of endothelial progenitor cells (EPCs), than nonmobilized PBMCs did (the Table) . Interestingly, reversetranscription polymerase chain reaction (RT-PCR) and flow cytometry showed significantly greater Tie2 expression in mob PBSCs than in PBMCs from AMI or SA patients (Tie2positive fraction in flow cytometry analysis: 19.2Ϯ3.0% versus 1.2Ϯ0.8% versus 1.2Ϯ0.2%; PϽ0.001 for mob PBSCs versus PBMC_AMI versus PBMC_SA; Figure 1A and 1B; quantitative RT-PCR data are given in Figure I to investigate the utility of the Tie2 agonist cartilage oligomeric matrix protein (COMP)-Ang1 (an Ang1 recombinant chimera) as a priming agent.
Long-Term Stimulation of mob PBSCs With COMP-Ang1 Increases the Number of Endothelial Lineage Cell Clusters
We tested the effect of COMP-Ang1 on the commitment of naïve PBMCs and mob PBSCs, both from AMI patients, into endothelial lineage cells. They were seeded in EPC culture media 4 containing COMP-Ang1 (400 ng/mL), and 5 to 7 days later, clusters of attached cells were observed. The cluster number of naïve PBMCs did not change even after COMP-Ang1 treatment for 7 days compared with vehicle (nϭ12; Pϭ0.65; Figure 2A ). However, the cluster number of mob PBSCs after COMP-Ang1 treatment for 7 days increased Ϸ2-fold compared with vehicle (94Ϯ18% increase; nϭ12; PϽ0.01; Figure 2B ). These clusters were composed of spindle-shaped cells similar to EPCs. To determine the phenotype of the increased clusters in mob PBSC group, we performed immunocytochemical staining using antibodies for CD31, CD34, VEcadherin, Tie2, CXCR4, and KDR. Clusters were stained positive 7 days after cultivation with COMP-Ang1 ( Figure 2C ).
Short-Term Stimulation of mob PBSCs With COMP-Ang1 Increases Endothelial Lineage Commitment Through Tie2/Ets-1 Signaling
Among the positively stained surface markers of the clusters, KDR, VE-cadherin, and Tie2 are all known to contain Ets-1 transcription factor binding sites in their promoter regions. 11 Thus, we investigated whether the effect of COMP-Ang1 on the lineage commitment of mob PBSCs is mediated via the transcriptional regulation of Ets-1. The gene expression of Ets-1 did not change significantly after the stimulation of naïve PBMCs with COMP-Ang1 ( Figure 3A ). In mob PBSCs, however, expression of Ets-1 mRNA increased 2 hours after stimulation with COMP-Ang1 ( Figure 3B ; quantitative RT-PCR data are given in Figure II of the online-only Data Supplement). Furthermore, we pretreated mob PBSCs with anti-Tie2 neutralizing antibody 1 hour before COMP-Ang1 treatment and found that blockage of Tie2 receptor reduced the expression of Ets-1 mRNA ( Figure 3C ; quantitative RT-PCR data are given in Figure III of the online-only Data Supplement). Next, we examined whether short-term stimulation of naïve PBMCs or mob PBSCs with COMP-Ang1 might induce Long-term stimulation of mob PBSCs with COMP-Ang1 increases the number of endothelial lineage cell clusters, which is not observed in naïve PBMCs. A, After 7 days of culture in EPC culture media, naïve PBMCs showed cell clusters composed of spindleshaped cells. The number of clusters was not affected by continuous treatment with COMP-Ang1 (400 ng/mL) for 7 days vs vehicle. Scale barϭ400 m. B, However, the number of clusters of mob PBSCs increased after continuous treatment with COMP-Ang1 vs treatment with vehicle alone (nϭ12; *PϽ0.01). Scale barϭ400 m. C, Immunocytochemical staining of the clusters from mob PBSCs revealed that they were committed to endothelial lineage. Scale barϭ100 m. endothelial lineage commitment. In naïve PBMCs, COMP-Ang1 treatment for 4 hours did not affect the expression of endothelial specific genes such as CD31 and VE-cadherin compared with vehicle treatment ( Figure 3D and 3E). In mob PBSCs, however, COMP-Ang1 treatment resulted in stronger expression of CD31 and VE-cadherin, which was reversed by antisense Ets-1 oligodeoxynucleotides ( Figure 3F ; quantitative RT-PCR data are given in Figure IV of the online-only Data Supplement). These results were confirmed at the protein level by flow cytometry analysis ( Figure 3G ) in which short-term treatment with COMP-Ang1 increased the expression of CD31 and VE-cadherin by 51Ϯ10% and 118Ϯ13%, which was abrogated by transfection of mob PBSCs with antisense Ets-1 oligodeoxynucleotides by 56Ϯ7% and 46Ϯ5%.
Priming of mob PBSCs With COMP-Ang1 Activates ␣4␤1 and ␣5␤1 Integrins
As shown above, the short-term stimulation of mob PBSCs with COMP-Ang1 induced Ets-1 expression. Moreover, a previous report showed that ␤3 integrin was downstream of Ets-1 activation. 11 Therefore, we postulated that other integrins that contain an Ets-1 binding motif in their promoter region may be activated by COMP-Ang1 such as ␣4␤1 and ␣5␤1 integrins, both of which are known to play key roles in the homing and retention of stem/progenitor cells in bone marrow. 12 Thus, we measured the expression of these integrins after short-term treatment with COMP-Ang1. The stimulation of naïve PBMCs with COMP-Ang1 for 4 hours did not change the mRNA and protein expression of ␣4, ␣5, and ␤1 integrin ( Figure 4A and 4B). However, stimulation of mob PBSCs with COMP-Ang1 increased the expression of ␣4, ␣5, and ␤1 integrin (flow cytometry analysis: 107Ϯ39%, 51Ϯ24%, and 78Ϯ21% increase for ␣4, ␣5, and ␤1 integrin, respectively; Figure  4C and 4D; quantitative RT-PCR data are given in Figure  V of the online-only Data Supplement), and antisense Ets-1 oligodeoxynucleotides attenuated this expression (flow cytometry analysis: 45Ϯ3%, 29Ϯ7%, and 36Ϯ9% decrease for ␣4, ␣5, and ␤1 integrin, respectively). We also investigated the expression of ␤2 integrin, which is another key molecule for EPC homing, 13 but its mRNA and protein expression did not change significantly after COMP-Ang1 treatment in both the naïve PBMC and mob PBSC groups even though it was highly expressed at baseline.
To correlate these findings with functional changes in mob PBSCs, we performed in vitro adhesion assays between ␣4␤1 on mob PBSCs and vascular cell adhesion molecule-1 on human umbilical vein ECs (HUVECs) and between ␣5␤1 on mob PBSCs and fibronectin. COMP-Ang1 stimulation for 4 hours increased mob PBSC adhesion to HUVECs (150Ϯ19% increase) and fibronectin (152Ϯ9% increase; Figure 4E and 4F), whereas pretreatment with anti-Tie2 neutralizing antibody or anti-integrin antibody (anti-␣4 or -␣5) before COMP-Ang1 stimulation abrogated the increased adhesion, suggesting a Tie2-dependent increase in cell-to-cell and cell-to-matrix adhesion after COMP-Ang1 stimulation. Priming of mob PBSCs with COMP-Ang1 increases endothelial lineage commitment through Ets-1 and Tie2 signaling, which is not observed in naïve PBMCs. A, Temporal expression of Ets-1 in naïve PBMCs treated with COMP-Ang1 was evaluated by RT-PCR. Treatment with COMP-Ang1 did not significantly change Ets-1 expression. M indicates the molecular weight marker. B, RT-PCR addressed that treatment of mob PBSCs with COMP-Ang1 increased Ets-1 expression within 2 hours and sustained the expression for 10 hours. C, Ets-1 expression was mediated through Tie2 receptor. RT-PCR showed that Ets-1 mRNA expression increased in mob PBSCs treated with COMP-Ang1 for 4 hours, whereas 1-hour pretreatment with anti-Tie2 neutralizing antibody before COMP-Ang1 treatment prevented Ets-1 upregulation. D, RT-PCR showed that the expression of CD31 and VE-cadherin mRNA in naïve PBMCs did not change after treatment with COMP-Ang1 for 4 hours. E, Flow cytometry analysis showed results similar to RT-PCR. In naïve PBMCs, COMP-Ang1 did not affect the expression of CD31 or VE-cadherin. F, However, COMP-Ang1 stimulated the commitment of mob PBSCs to endothelial lineage, which was mediated by Ets-1 signaling. RT-PCR showed that the expression of CD31 and VE-cadherin mRNA was elevated after COMP-Ang1 stimulation for 4 hours. However, these upregulations were prevented by the prior transfection of antisense Ets-1 oligodeoxynucleotides. G, Flow cytometry analysis confirmed the expression at the protein level.
Priming of mob PBSCs With COMP-Ang1 Increases Matrigel Tube Formation and Incorporation Ability of mob PBSCs
Next, we investigated whether short-term stimulation of mob PBSCs with COMP-Ang1 might induce vasculogenesis even though there was no continuous stimulation with the growth factor. When primed mob PBSCs were cocultured with HUVECs, mob PBSCs and HUVECs produced significantly more complete tubes as determined by tube number, area, and length after 3 days (59Ϯ5%, 35Ϯ10%, and 37Ϯ5% increase for tube number, area, and length, respectively; Figure 5A ). Again, pretreatment with anti-Tie2 neutralizing antibody before COMP-Ang1 stimulation abrogated tube formation of mob PBSCs treated with COMP-Ang1 (44Ϯ8%, 35Ϯ11%, and 36Ϯ9% decrease for tube number, area, and length, respectively). In addition, more mob PBSCs were incorporated into . Activation of ␣4␤1 and ␣5␤1 integrins in mob PBSCs by COMP-Ang1, which is not observed in naïve PBMCs. A, RT-PCR showed that the stimulation of naïve PBMCs with COMP-Ang1 for 4 hours did not significantly change the expression of ␣4, ␣5, ␤1, and ␤2 integrin. B, Flow cytometry analysis showed results similar to RT-PCR. C, RT-PCR showed that the stimulation of mob PBSCs with COMP-Ang1 for 4 hours increased the expression of ␣4, ␣5, and ␤1 integrin, but this was prevented by prior transfection with antisense Ets-1 oligodeoxynucleotides. However, ␤2 integrin mRNA expression was not affected by COMP-Ang1 or by antisense Ets-1 oligodeoxynucleotide transfection. D, Flow cytometry analysis confirmed the above results at the protein level. E, COMP-Ang1 stimulation for 4 hours induced mob PBSC adhesion to HUVEC monolayers (nϭ4 each; *PϽ0.01 vs vehicle). Pretreatment of anti-Tie2 neutralizing antibody or anti-␣4 integrin (a known countermolecule for vascular cell adhesion molecule-1) antibody prevented this adhesion (#PϽ0.01 vs COMP-Ang1). F, COMP-Ang1 stimulation induced mob PBSC adhesion to fibronectin (nϭ4 each; *PϽ0.01 vs control). However, pretreatment with anti-Tie2 neutralizing antibody or anti-␣5 integrin (a known countermolecule for fibronectin) antibody prevented this adhesion (#PϽ0.01 vs COMP-Ang1).
Matrigel tubes when primed with COMP-Ang1, which was retarded when pretreated with anti-Tie2 neutralizing antibody (207Ϯ28% increase by priming and 66Ϯ2% decrease by Tie2 pre-blocking; Figure 5B ).
Priming of mob PBSCs With COMP-Ang1 Enhances the First-Pass Engraftment Into the Distal Vascular Bed of a Rabbit Ear Ischemia/Reperfusion Model After Intraarterial Delivery
Next, we investigated whether short-term stimulation with COMP-Ang1 may enhance the engraftment of PBMCs in the distal ischemic tissue after intraarterial delivery. For this examination, we developed a rabbit ear model of ischemia and reperfusion ( Figure 6A ). Scintigrams of ischemic rabbit ear after infusion of naïve PBMCs and unprimed mob PBSCs showed scanty engraftment in the ischemic ear ( Figure 6B and 6C). In contrast, mob PBSCs primed with COMP-Ang1 showed markedly increased engraftment by 53Ϯ33% (nϭ6; PϽ0.01), which was reversed by pretreatment of mob PBSCs with anti-Tie2 neutralizing antibody before COMP-Ang1 priming. Specific examinations of the tissue with immunofluorescent staining showed the same results ( Figure VI 
Priming of mob PBSCs With COMP-Ang1 Enhances Engraftment and Neovascularization of the Ischemic Limb After Arterial Infusion
We next investigated whether injection of COMP-Ang1primed mob PBSCs enhanced neovascularization in vivo using a hind-limb ischemia model. COMP-Ang1-primed mob PBSCs from patients were administered via intracardiac puncture into athymic nude mice after the induction of hind-limb ischemia. COMP-Ang1-primed mob PBSC infusion improved limb perfusion compared with unprimed mob PBSC infusion (perfusion ratio of ischemic to nonischemic limbs at day 21, 49.3Ϯ13.8% versus 34.9Ϯ3.0%; nϭ10 each, PϽ0.01 for primed versus unprimed mob PBSC infusion), which was reversed by pretreatment with anti-Tie2 neutralizing antibody (perfusion ratio at day 21, 33.6Ϯ7.4%; nϭ10; PϽ0.05 versus Figure 5 . Priming of mob PBSCs with COMP-Ang1 increases Matrigel tube formation and incorporation ability of mob PBSCs. A, Tube formation assays on the Matrigel in vitro. When cocultured with HUVECs, mob PBSCs primed with COMP-Ang1 for 4 hours showed more complete tube formation (*PϽ0.05 vs control; #PϽ0.05 vs COMP-Ang1). Scale barϭ200 m. B, mob PBSCs labeled with CFSE (green) were cocultured with HUVECs. mob PBSCs primed with COMP-Ang1 for 4 hours were incorporated more into HUVEC tubes than mob PBSCs treated with vehicle. Moreover, the incorporation was prevented by pretreatment of anti-Tie2 neutralizing antibody (*PϽ0.01 vs control; #PϽ0.01 vs COMP-Ang1). Scale barϭ50 m.
COMP-Ang1-primed group; Figure 7A ). Moreover, we assessed the neovasculogenic effect of PBMC_AMI. The naïve PBMCs were inferior to even unprimed mob PBSCs in terms of blood flow recovery (perfusion ratio ischemic to nonischemic limbs at day 21, 22.6Ϯ7.3% versus 34.9Ϯ3%; nϭ10 each; PϽ0.05 for naïve PBMCs versus unprimed mob PBSC infusion).
Histologically, we observed more capillaries in the ischemic limb that received COMP-Ang1-primed cells (192Ϯ15% increase; nϭ6; PϽ0.01; Figure 7B and 7C). Next, to determine the contribution of engrafted cells to neovascularization, we checked cellular engraftment using carboxyfluorescein succinimidyl ester (CFSE) -labeled mob PBSCs and performed immunohistochemical staining with human-specific and vessel markers. More CFSE-labeled mob PBSCs (Figure 7D and 7E) and human-specific von Willebrand factor-and HLApositive cells ( Figure 7F and Figure VII of the online-only Data Supplement) were detected in the ischemic hind limb treated with COMP-Ang1-primed cells than with the unprimed cells. Furthermore, confocal analysis of immunofluorescent staining demonstrated that there were more cells double positive for human HLA and CD31 ( Figure 7G ) in the COMP-Ang1 priming group. Because cell-to-cell adhesion through binding of ␣4␤1 integrins with vascular cell adhesion molecule-1 plays a greater role in the homing of injected PBSCs than cell-to-fibronectin adhesion, 14 we examined the expression of ␣4 integrin. We found that ␣4-positive cells increased in the ischemic hind limb treated with COMP-Ang1-primed mob PBSCs. The cells positive for ␣4 integrin were colocalized with human-specific HLA and engrafted into areas of vascular regeneration. Pretreatment of anti-Tie2 neutralizing antibody reversed this phenomenon ( Figure 7H ).
Systemic Administration of G-CSF Does Not Enhance Vasculogenesis in Mouse Ischemic Hind Limb but COMP-Ang1 Does
We also compared the effects of systemic administration of COMP-Ang1 and G-CSF on the vasculogenesis in the mouse ischemic hind-limb model. On day 3 after the intravenous injection of recombinant adenovirus-expressing COMP-Ang1 or LacZ (vehicle), C57BL/6 mice underwent unilateral femoral artery excision (nϭ6 in each group). Then, G-CSF or sterile saline was injected subcutaneously for 3 days (vehicle group, Ade-LacZ plus saline injection; COMP-Ang1 group, Ade-COMP-Ang1 plus saline injection; G-CSF group, Ade-LacZ plus G-CSF injection; combined cytokine group, Ade-COMP-Ang1 plus G-CSF injection).
When followed up at 14 days, the systemic administration of G-CSF did not improve neovascularization compared with vehicle, whereas COMP-Ang1 significantly improved perfusion. The combined cytokine group showed a result similar to the COMP-Ang1 alone group, suggesting no positive interaction between systemic administration of G-CSF and COMP-Ang1 (the perfusion ratio of ischemic to nonischemic limbs at day 14, 59.1Ϯ3.6% versus 71.4Ϯ4.8% versus 56.8Ϯ4.1% versus 71.8Ϯ3.6%; nϭ6 each; PϽ0.01 for vehicle versus COMP-Ang1 versus G-CSF versus combined cytokine; Figure 8A and 8B) . In the histological analysis, systemic administration of G-CSF did not increase capillary density, whereas COMP-Ang1 or combined cytokines increased it compared with vehicle (78Ϯ10% increase by COMP-Ang1 and 67Ϯ10% increase by combined cytokines; nϭ6 each; PϽ0.01 versus vehicle by 1-way ANOVA with Tukey analysis; Figure 8C ).
Discussion
Ang1 has been reported to be important for blood vessel formation in the embryonic period, and blood vessels in the Ang1 Ϫ/Ϫ mice had fewer ECs and showed defects in the association of the endothelium with the extracellular matrix and vessel rupture. 15 This phenomenon suggests the possibility that Ang1 contributes to the differentiation and homing of primitive stem cells that participate in new vessel formation. The recently developed synthetic COMP-Ang1, an Ang1 Figure 6 . Effect of COMP-Ang1 stimulation on the engraftment of mob PBSCs into the distal vascular bed after intraarterial infusion in a rabbit ear ischemia/reperfusion model. A, Schematic of in vivo adhesion assay to evaluate the efficiency of first-pass engraftment of mob PBSCs into ischemic tissue after intraarterial delivery. mob PBSCs were obtained from G-CSF-treated rabbit peripheral blood. Cells were labeled with CFSE and Tc-99m HMPAO (1 mCi per 1ϫ10 7 ). Another rabbit was prepared for ischemia/reperfusion. A proximal portion of the ear central artery was ligated for 3 hours and then released. The radiolabeled mob PBSCs were subsequently injected into a central artery. To evaluate the first-pass engraftment, the ear was harvested immediately after cell delivery. B, Engrafted PBMCs and mob PBSCs in a reperfused vessel in scintigrams. Priming of mob PBSCs with COMP-Ang1 showed a higher efficiency of firstpass engraftment than naïve PBMCs or untreated mob PBSCs. C, Radioactivity measured by a gamma counter. PBMC engraftment was quantified by the ratio of whole rabbit ear radioactivity after intraarterial infusion to total infused PBMC radioactivity. Priming of mob PBSCs with COMP-Ang1 increased engraftment (nϭ6 each; *PϽ0.01 vs control; #PϽ0.01 vs COMP-Ang1). Pretreatment of mob PBSCs with anti-Tie2 neutralizing antibody abrogated this increase.
Figure 7.
Effect of mob PBSCs primed with COMP-Ang1 on neovascularization in a murine model of hind-limb ischemia. A, Perfusion ratio of ischemic to nonischemic limb measured by laser Doppler perfusion image analyzer. Repeated-measures ANOVA with Scheffé contrast showed a significant perfusion improvement in the COMP-Ang1-primed mob PBSC group (PϽ0.05). Data are meanϮSEM. nϭ10 in each group. †PϽ0.05 vs unprimed mob PBSC group. B and C, Treatment with COMP-Ang1-primed mob PBSCs generated more capillaries in the ischemic limbs than unprimed mob PBSCs (nϭ6 each; *PϽ0.01 vs control; #PϽ0.01 vs COMP-Ang1). Red indicates BS-1 lectin for murine vessels; blue, DAPI for nuclei. D and E, CFSE-labeled mob PBSCs (green) primed with COMP-Ang1 were observed more variant that is both soluble and stable, is known to be more potent than native Ang1 in activating Tie2 in ECs 16 and to augment new vessel formation in various disease models. 16, 17 The rationale for using COMP-Ang1 as a priming agent was our new finding that mob PBSCs express high levels of Tie2. We hypothesized that because of the high expression of the Tie2 receptor in mob PBSCs, these cells would be excellent candidates to embrace the various beneficial effects of COMP-Ang1. Our data showed that endothelial lineage commitment and functional upregulation of integrins occurred within 4 hours of treatment in the mob PBSC group, which means that priming of mob PBSCs can be performed in a short-term and simple manner and may be a clinically feasible method. Neovascularization can be mediated by the vasculogenic potential of mob PBSCs, which can differentiate and acquire endothelial phenotype. G-CSF is well known to potently mobilize hematopoietic stem cells from bone marrow. 18 Moreover, AC133 ϩ CD34 ϩ cells, subsets of mob PBSCs, are considered to have the potential to differentiate to ECs and the ability to home to ischemic sites, resulting in neovascularization in adults. 19 Thus, we hypothesized that enhancement of the endothelial commitment of mob PBSCs could augment neovascularization in ischemic tissue. In this study, the culture of mob PBSCs with COMP-Ang1 induced more EPC clusters compared with vehicle. In addition, priming of mob PBSCs with COMP-Ang1 for 4 hours enhanced the endothelial commitment of mob PBSCs and vasculogenesis in the Figure 7 (Continued) . frequently in the ischemic muscle at day 21. nϭ6 in each group. *PϽ0.01 vs control; #PϽ0.01 vs COMP-Ang1. F, Immunohistochemical staining showed that human-specific von Willebrand factor (vWF) -positive cells were significantly increased in ischemic limb of a nude mouse treated with COMP-Ang1-primed mob PBSCs from patients. Scale barsϭ50 m. G, Confocal analysis showed that COMP-Ang1-primed mob PBSCs from patients were committed to the endothelial lineage in nude mouse ischemic hind limb. Green indicates CD31; red, anti-HLA; and blue, DAPI. Scale barsϭ20 m. H, Representative confocal images indicated that COMP-Ang1-primed mob PBSCs from patients were engrafted to nude mouse ischemic muscle through the activation of ␣4 integrins. Green indicates ␣4 integrins; red, anti-HLA; and blue, DAPI. Scale barsϭ20 m. Matrigel. In a nude mouse hind-limb model, animals treated with mob PBSCs primed by COMP-Ang1 showed more capillaries that were composed of injected mob PBSCs than animals treated with unprimed mob PBSCs. To the best of our knowledge, this is the first report to demonstrate the effect of COMP-Ang1 on mob PBSC commitment to endothelial lineage cells.
The direct physical incorporation of mob PBSCs into the ischemic site is another important process for neovascularization. 20 However, the mechanisms whereby mob PBSCs home to sites of ischemia are unclear. Before stem/progenitor cells are mobilized to the circulation, they interact with the bone marrow microenvironment. 21 Ang1 is released from the microenvironment and contributes to the retention of PBSCs in the marrow by Tie2 and integrin signaling. 22, 23 Here, we hypothesized that the interaction between Ang1 and Tie2 and subsequent activation of integrins would be important not only for retainment in bone marrow but also for stem-cell homing to injured myocardium. In this study, the transcription of ␣4, ␣5, and ␤1 integrins was upregulated after short-term COMP-Ang1 treatment. Moreover, COMP-Ang1primed mob PBSCs were incorporated more abundantly into the tube formation process. In addition, COMP-Ang1 priming increased first-pass engraftment of mob PBSCs in the distal vascular bed after intraarterial delivery in a rabbit ear model. In a murine hind-limb ischemia model, we showed greater engraftment of injected human mob PBSCs treated with COMP-Ang1 in areas of new vessel growth, and this phenomenon was mediated by the expression of ␣4 integrin in response to COMP-Ang1. These findings suggest that priming with Ang1 would play an important role in the initial engraftment of mob PBSCs to ischemic tissue by upregulating those integrins and would help to overcome the poor engraftment of mob PBSCs, which would be useful for clinical settings when cells are delivered through artery.
Among the homing mechanisms of stem/progenitor cells, the interaction between stromal cell-derived factor 1 and CXCR4 also has been known to play an important role in homing to injured myocardium. 24 Recently, Honold et al 25 reported that in the situation of mobilization with G-CSF, CXCR4 on the surface of mobilized EPCs may be degraded, leading to the decreased efficiency of homing to ischemic tissue driven by stromal cell-derived factor 1. However, our results showed that Ang1-primed mob PBSCs were very effective in promoting neovascularization even if they were mobilized by G-CSF. The reason for the difference between 2 studies may be explained as follows. First, we selected patients with AMI rather than with chronic ischemic heart disease. Second, freshly isolated mob PBSCs were different from EPCs obtained several days after ex vivo cultivation. Third, they did not present the total amount of CXCR4 in EPCs, even though some might be disrupted after G-CSF mobilization. We found that the total number of CXCR4 receptors in mob PBSCs was Ϸ3-fold higher than in nonmobilized PBMCs (CXCR4-positive fraction in flow cytometry analysis: 34.2Ϯ16.7% versus 11.7Ϯ8.8%; PϽ0.01 for mob PBSCs versus PBMC_AMI; Figure VIII of the online-only Data Supplement). Therefore, the total number of the functionally active CXCR4 receptors in mob PBSCs may not be lower or even higher than that of naïve PBMCs. Finally, this new priming strategy with COMP-Ang1 for G-CSF-mobilized stem/progenitor cells, including EPCs, may turn on the other homing mechanism mediated by integrin-vascular cell adhesion molecule-1 or integrin-fibronectin, which can overcome the possible impaired interaction between stromal cell-derived factor 1 and CXCR4.
Another novel finding of the present study is that the effect of COMP-Ang1 is mediated through Tie2/Ets-1 signaling. Ets-1 is the prototype of the Ets family transcription factors and is well known to be expressed in ECs during angiogenesis. 11 However, few studies have addressed the effect of Ets-1 transcription factor in mob PBSCs on adult vasculogenesis. Previous reports documented that Ets-1 increased the expression of some matrix metalloproteinases, urokinase-type plasminogen activator, and integrin ␤3 in ECs. 26 Other reports showed that VE-cadherin and endothelium-specific receptor-type tyrosine kinases such as Flt-1, KDR, Tie1, and Tie2 contained the Ets binding motif in their promoter/ enhancer regions in ECs, and Ets family transcription factors were suggested to stimulate their promoter activities. 11 In the present study, the transcription of Ets-1 in mob PBSCs significantly increased after COMP-Ang1 treatment, which was reversed after Tie2 blocking, indicating that Ets-1 is downstream of the Tie2 signaling. In addition, CD31 and VEcadherin, markers of endothelial commitment, which were upregulated after the treatment of mob PBSCs with COMP-Ang1, were downregulated after antisense Ets-1 treatment, suggesting that the endothelial commitment of mob PBSCs by COMP-Ang1 is dependent on Ets-1 signaling. Relative to the expression of various integrins, Ets-1 blockade reversed the upregulation of ␣4, ␣5, and ␤1 integrins by COMP-Ang1, suggesting that the expression of integrins is also under the regulation of Ets-1 signaling. Therefore, Ets-1 may be an important mediator of the proangiogenic effects of priming of mob PBSCs with COMP-Ang1.
Conclusions
Our results show that priming of mob PBSCs with COMP-Ang1, via the Tie2/Ets-1 pathway, significantly induces their endothelial commitment and upregulates their expression of integrins, leading to enhancement of engraftment even after intravascular delivery and new vessel formation in the ischemic tissue ( Figure IX of the online-only Data Supplement). These data suggest that short-term priming of stem/progenitor cells with COMP-Ang1 can be a feasible and promising option to functionally augment mob PBSCs and to enhance the therapeutic efficacy of cell therapy in clinical situations. 
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